Literature DB >> 24408051

Quality of life, social situation, and sexual satisfaction, in adult males with congenital adrenal hyperplasia.

Henrik Falhammar1, Helena Filipsson Nyström, Marja Thorén.   

Abstract

To determine quality of life (QoL) in adult males with congenital adrenal hyperplasia (CAH). CAH males with 21-hydroxylase deficiency (n = 30), 19-67 years old, were compared with controls (n = 32). QoL was assessed using questionnaires on general living conditions and sexual issues, and the psychological well-being index (PGWB) form. Fewer CAH males than controls were students (3 vs. 25 %, P = 0.028) and more had blue-collar work (57 vs. 33 %, P = 0.023). Patients were less interested in sports (47 vs. 72 %, P = 0.034) and art/literature/film (10 vs. 47 %, P = 0.004). PGWB total score was 82.7 ± 13.7 versus 87.0 ± 11.1 (P = NS), but hydrocortisone/cortisone acetate treated scored lower than controls and prednisolone treated. Glucocorticoid over-treated had lower QoL than those with poor control (PGWB total score 77.1 ± 13.5 vs. 92.4 ± 11.1, P = 0.026) and controls (P = 0.025). Total PGWB score was positively correlated with adrenal androgens and steroid precursors. Subscale scores indicated that patients with late diagnosis were more depressive (12.1 ± 2.8 vs. 13.9 ± 1.4, P = 0.011) and had a lower self-control (11.3 ± 3.6 vs. 13.1 ± 1.0, P = 0.019) compared with controls. Sexual satisfaction was similar in spite of more patients being sexually inactive (27 vs. 6 %, P = 0.040). Adult CAH males differed from controls with respect to type of occupation and spare time interests but had similar QoL despite being less sexually active. Optimizing glucocorticoid therapy might further improve QoL. Some disadvantages found in patients diagnosed late will hopefully not be seen in patients diagnosed by neonatal screening, but this has yet to be studied.

Entities:  

Mesh:

Year:  2014        PMID: 24408051     DOI: 10.1007/s12020-013-0161-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

1.  Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency.

Authors:  Nicole Reisch; Stefanie Hahner; Benjamin Bleicken; Linda Flade; Francesco Pedrosa Gil; Melanie Loeffler; Manfred Ventz; Andreas Hinz; Felix Beuschlein; Bruno Allolio; Martin Reincke; Marcus Quinkler
Journal:  Clin Endocrinol (Oxf)       Date:  2011-02       Impact factor: 3.478

2.  Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Helena Filipsson; Gundela Holmdahl; Per-Olof Janson; Agneta Nordenskjöld; Kerstin Hagenfeldt; Marja Thorén
Journal:  J Clin Endocrinol Metab       Date:  2006-10-10       Impact factor: 5.958

3.  Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway.

Authors:  Ingrid Nermoen; Eystein S Husebye; Johan Svartberg; Kristian Løvås
Journal:  Eur J Endocrinol       Date:  2010-06-15       Impact factor: 6.664

4.  Improvement of health-related quality of life in adult women with 21-hydroxylase deficiency over a seven-year period.

Authors:  Benjamin Bleicken; Manfred Ventz; Andreas Hinz; Marcus Quinkler
Journal:  Endocr J       Date:  2012-06-30       Impact factor: 2.349

Review 5.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

6.  Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Helena Filipsson; Gundela Holmdahl; Per-Olof Janson; Agneta Nordenskjöld; Kerstin Hagenfeldt; Marja Thorén
Journal:  J Clin Endocrinol Metab       Date:  2007-09-18       Impact factor: 5.958

7.  Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia.

Authors:  Agneta Nordenskjöld; Gundela Holmdahl; Louise Frisén; Henrik Falhammar; Helena Filipsson; Marja Thorén; Per Olof Janson; Kerstin Hagenfeldt
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

Review 8.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

9.  Androgen and psychosexual development: core gender identity, sexual orientation and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH).

Authors:  Melissa Hines; Charles Brook; Gerard S Conway
Journal:  J Sex Res       Date:  2004-02

10.  Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia.

Authors:  T S Han; R H Stimson; D A Rees; N Krone; D S Willis; G S Conway; W Arlt; B R Walker; R J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  2013-02       Impact factor: 3.478

View more
  17 in total

1.  Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency.

Authors:  M Delvecchio; L Soldano; A Lonero; A Ventura; P Giordano; L Cavallo; M Grano; G Brunetti; M F Faienza
Journal:  Endocrine       Date:  2014-07-01       Impact factor: 3.633

Review 2.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 3.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

4.  Psychological stress, emotions, and quality of life in men and women with congenital adrenal hyperplasia.

Authors:  L Lašaitė; R Navardauskaitė; K Semėnienė; R Verkauskienė
Journal:  J Endocrinol Invest       Date:  2022-05-25       Impact factor: 5.467

Review 5.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

Review 6.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

7.  Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil.

Authors:  Daniel Luis Schueftan Gilban; Paulo Alonso Garcia Alves Junior; Izabel Calland Ricarte Beserra
Journal:  Health Qual Life Outcomes       Date:  2014-08-13       Impact factor: 3.186

Review 8.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

9.  Bone Mineral Density in Adults With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Swetha Rangaswamaiah; Vinay Gangathimmaiah; Anna Nordenstrom; Henrik Falhammar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

10.  Psychological adjustment, quality of life, and self-perceptions of reproductive health in males with congenital adrenal hyperplasia: a systematic review.

Authors:  Elisabeth Daae; Kristin Billaud Feragen; Ingrid Nermoen; Henrik Falhammar
Journal:  Endocrine       Date:  2018-08-20       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.